This session, presented by Mikkael Sekeres, MD, Chief of the Division of Hematology at the University of Miami Health System, will focus on predictive and prognostic markers for myelodysplastic syndromes (MDS), emerging data on novel therapies, and strategies to optimize safety and tolerability for patients with this disease.
Presented by Amir Fathi, MD, Associate Professor of Medicine at Harvard Medical School, this session will highlight individualized treatment selection for patients with acute lymphoblastic leukemia (ALL), as well as recent efficacy and safety data for novel therapeutic strategies.
In this session, Morie Gertz, MD, Chair of General Internal Medicine at the Mayo Clinic in Minnesota, will discuss how to use predictive and prognostic markers to select treatment for patients with Waldenstrom macroglobulinemia (WM) and how to appraise emerging clinical trial data and adverse event management strategies for novel treatments.
Louis Diehl, MD, Professor of Medicine at Duke University Medical School, will discuss strategies for incorporating predictive and prognostic markers, recent efficacy and safety data, and adverse event management strategies into treatment selection for patients with Hodgkin lymphoma (HL).
In this session, John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine, will share insights on predictive and prognostic markers, emerging efficacy and safety data, and strategies to optimize tolerability for patients receiving novel therapies for mantle cell lymphoma (MCL).
After the conference, join us for a special networking session with our expert faculty presenters. Attendees will have the opportunity to speak with faculty one-on-one and receive additional advice from the presenters. *This session requires additional fees.
Amir Fathi, MD, is an Associate Professor of Medicine at Harvard Medical School and the Program Director of the Center for Leukemia and Massachusetts General Hospital. He specializes in the treatment of patients with acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes, and myeloproliferative diseases. Dr. Fathi’s research focuses of the development of novel treatments for acute leukemias, with particular interest in FLT3 inhibition, aurora kinase inhibition, and antibody-drug conjugates, and he currently serves as primary investigator of several clinical trials.
Louis Diehl, MD, is a Professor of Medicine at Duke University Medical School and a Member of the Duke Cancer Institute in Durham, North Carolina. He specializes in the treatment of patients with Hodgkin lymphoma, non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, and other hematological malignancies. Dr. Diehl has authored or coauthored more than 300 publications focused on developing novel treatments and improving outcomes for patients with lymphoma and other hematological diseases.
Morie Gertz, MD, is the Roland Seidler Jr. Professor in the Department of Medicine and Chair of General Internal Medicine at the Mayo Clinic in Rochester, Minnesota. He specializes in the treatment of patients with Waldenstrom macroglobulinemia, amyloidosis, and multiple myeloma, including those undergoing stem cell transplantation. Dr. Gertz serves as a member of the American Board of Internal Medicine’s Hematology Approval Committee, and he has authored or coauthored more than 700 manuscripts focusing on research for hematological malignancies.
John Leonard, MD, is the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, the Senior Associate Dean for Innovation and Initiatives, and the Executive Vice Chairman of the Department of Medicine at Weill Cornell Medicine in New York. In addition, he is an attending physician at New York Presbyterian Hospital. Dr. Leonard specializes in the treatment of patients with mantle cell lymphoma, Hodgkin lymphoma, multiple myeloma, and other hematological malignancies. He has served as an investigator of numerous clinical trials focusing on novel therapeutics for hematological cancers.
Mikkael Sekeres, MD, is a Professor of Medicine and Chief of the Division of Hematology at the University of Miami Health System, where he specializes in the treatment of patients with myelodysplastic syndromes and older patients with acute myeloid leukemia. Dr. Sekeres has served as primary study investigator of dozens of clinical trials, and he has authored or coauthored over 400 manuscripts, 600 meeting abstracts, and 8 books. He serves on the Executive Committee of the American Society of Hematology and as a member of Southwest Oncology Group Leukemia Committee.
All schedule of events are in Eastern Daylight Time(EDT). The conference will begin at 8:00 AM EDT.